CClinicalTrials.gg
CompletedNCT04396119Updated Sep 3, 2020

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

An observational study in Hodgkin Lymphoma, sponsored by The Christie NHS Foundation Trust. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-03.

Sponsored by The Christie NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Read the detailed description

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

02

Conditions studied

  • Hodgkin Lymphoma
03

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 30 is below the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

The Christie NHS Foundation Trust is the lead sponsor of 99 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants who have previously been treated for Hodgkin lymphoma without evidence of relapse for at least 5 years

Inclusion criteria

  • Details held in the ADAPT database at The Christie NHS Foundation trust
  • Responded to most recent ADAPT study questionnaire (April - August 2019)
  • Aged 18-80
  • Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
  • Able to provide informed consent
  • Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • Previous or current diagnosis of lung cancer
  • Stated within 2019 health questionnaire that they did not wish to be contacted
  • Have participated in lung cancer screening through the Manchester Lung Health Checks
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Explore survivors' attitudes towards lung cancer and lung cancer screening

    Semi-structured interviews

    Time frame: 6 months

07

Study locations

1 site
  • Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — It is not intended to share IPD with other researchers outside the study team

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04396119
Lead sponsor
The Christie NHS Foundation Trust
Responsible party
Sponsor
First posted
May 20, 2020
Start date
Feb 11, 2020
Primary completion
Apr 13, 2020
Completion
Apr 13, 2020
Last update
Sep 3, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion